RxDoctor Payments Data

James Mersey, MD

Endocrinology, Diabetes & Metabolism · The Villages, FLNPI 1669477683

Payments from drug & device makers

$36,887in general payments, 2019–2025

Across 403 payments — averaging $91.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$27K
  • Amgen$2K
  • Novo Nordisk$1K
  • Medtronic$1K
  • Lilly USA, LLC$828
  • Abbott$703
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$24,60967%
  • Travel & lodging$7832%
  • Food & beverage$11,40831%
  • Education$280%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,887 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$47,499
Medicare patients
475
Services billed
3,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$86,945
TrulicityDulaglutide17$32,033
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$28,553
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$22,449
JardianceEmpagliflozin16$19,209
FarxigaDapagliflozin Propanediol11$15,248
Tresiba Flextouch U-100Insulin Degludec14$14,913
Humalog Kwikpen U-100Insulin Lispro22$6,521
SynthroidLevothyroxine Sodium62$5,819
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$2,627
Insulin Lispro Kwikpen U-100Insulin Lispro12$2,406
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,972
Liothyronine Sodium20$1,671
Levothyroxine Sodium112$1,170
Hydrocortisone21$1,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,255$86,94542 claims
Lilly USA, LLCTrulicity$828$32,03317 claims
Boehringer IngelheimJardiance$269$19,20916 claims
AstraZenecaFarxiga$211$15,24811 claims
AbbVieSynthroid$250$5,81962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →